Evogene

A computational biology and chemistry company leveraging AI to discover and develop innovative small-molecule products for the pharmaceutical and agricultural industries.

Health Tech & Life Sciences
Active
Public Rehovot, Israel Founded 2002
Last updated 2026-11-05
Total raised
$246.4M
Last: Public Offering 2026-07
Stage
Public
Founded
2002
Headcount
38
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of Evogene's offering is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters, increasing the probability of success while reducing development time and costs. Evogene operates through subsidiaries focused on human microbiome-based therapeutics (Biomica Ltd), medical cannabis (Canonic Ltd), agricultural biologicals (Lavie Bio Ltd), agriculture chemicals (AgPlenus Ltd), and castor oil production solutions (Casterra Ltd). Evogene has repositioned itself around ChemPass AI as its core engine, serving two main verticals: Pharma (discovery of novel small-molecule therapeutics) and Agriculture (crop protection innovation and related ag-tech applications).

Funding history · 26 rounds · $246.4M total

26 events/rounds · $246.4M Total Funding: $69.0M in Private Equity, $173.5M in Public Equity
Jul 2026
Public Offering $3.3M tipranks.com
Feb 2026
PIPE $3.4M prnewswire.com ↗
Jan 2026
Public Offering $800K investing.com ↗
Jan 2026
Public Offering $2.4M investing.com ↗
2025
D Round $11.1M ft.com ↗
Mar 2024
Public Offering $7.3M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2023
Public Offering $8.5M evogene.com
May 2023
Grant $1.3M EU CORDIS — Horizon Europe (Crop4Clima)
Dec 2022
C Round $20.0M forbes.com ↗
★ Shanghai Healthcare Capital (SHC)Shanghai Healthcare Capital
Mar 2022
Public Offering $19.4M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2021
Public Offering $28.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2020
Public Offering $12.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2016
Grant $975K EU CORDIS — H2020 (FutureAgriculture)
Nov 2013
Public Offering $73.8M evogene.com
★ Monsanto★ Barclays★ Jefferies★ Oppenheimer & Co.★ Piper Jaffray & Co.★ Credit Suisse Securities★ Deutsche Bank SecuritiesJP Morgan
Dec 2010
Grant $1.6M globes.co.il
★ Biogemma SAS
Jun 2009
B Round Undisclosed wikipedia.org
Sep 2008
A Round Undisclosed wikipedia.org
Jul 2008
PIPE $18.0M prior (startupim db)
Mar 2008
Public Offering Undisclosed prior (startupim db)
Mar 2008
PIPE $2.0M prior (startupim db)
Jun 2007
Public Offering $8.0M biospace.com
Apr 2007
Feb 2006
A Round $7.0M prior (startupim db)
Jan 2003
Seed $2.0M globes.co.il ↗
★ US investors★ Israeli investors★ European investors★ Israeli, European and US investorsCompugen

Acquisitions · 2

Jul 2025
Lavie Bio (majority activity) $15.3M
Jul 2025
MicroBoost AI for AG platform $3.5M

Offices

Rehovot, Israel · HQ / main office

Q&A

What is Evogene's core technology?
Evogene's core technology is ChemPass AI™, a proprietary generative AI engine designed to discover and develop novel small molecules for the pharmaceutical and agricultural industries.
What industries does Evogene target with its AI platform?
Evogene targets two main verticals with its ChemPass AI™ platform: Pharma, for the discovery of novel small-molecule therapeutics, and Agriculture, for crop protection innovation and related ag-tech applications.
What was Evogene's most recent funding event?
Evogene's most recent funding event was a Public Offering in July 2026, which raised $3,288,113. A.G.P./Alliance Global Partners participated in this round.
When was Evogene founded and where is it headquartered?
Evogene was founded in January 2002 and is headquartered in Rehovot, Israel.
What was the amount of the PIPE funding round Evogene received in August 2024?
In August 2024, Evogene received $5,500,000 in a PIPE funding round, with participation from Israel Innovation Authority and A.G.P./.
What was the amount of the C Round funding Evogene received in December 2022?
In December 2022, Evogene received $20,000,000 in a C Round funding, with Shanghai Healthcare Capital (SHC) participating.
What was the amount of the Public Offering in March 2024?
In March 2024, Evogene conducted a Public Offering that raised $7,300,000.

Team · 19

Rafi Meissner
Founder · founders
LinkedIn ↗
Hagai Karchi
Founder · founders
LinkedIn ↗
Ofer Haviv
President & CEO
Yaron Eldad
Chief Financial Officer
Gabi Tarcic
Chief Development Officer
Ilia Zhidkov
Chief Technology Officer
Liat Foigel Wejgman
Vice President of Human Resources
Polina Ravzin
Vice President of Finance
Olga Nissan
Vice President of Business Development
Nir Nimrodi
Chairman of the Board
Ofer Haviv
Board Member
Sarit Firon
Board Member
Dan Falk
Board Member
Adrian Percy
Board Member
Leon Y. Recanati
Board Member
Yael Margolin
Board Member
Yoshinori Oikawa
Board Member
John Irwin
Scientific Advisory Board
Dan Major
Scientific Advisory Board

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B

Highlights

Patents

Tags

computational-biologycomputational-chemistryartificial-intelligencegenerative-aismall-molecule-discoverypharmaceuticalsagricultureag-techcrop-protectionhuman-healthbiotechnologylife-sciences
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteevogene.com
LinkedInlinkedin.com/company/100603
Wikipediaen.wikipedia.org/wiki/Evogene
Wikidatawikidata.org/wiki/Q6981538

Identifiers & details

Legal nameEvogene Ltd.
Founded2002-1
Employees (exact)38
Wikidata QIDQ6981538

Acquisitions & public offerings

AcquiredDateAmount
Lavie Bio (majority activity)2025-07$15.3M
MicroBoost AI for AG platform2025-07$3.5M

Radar intelligence

Patents

EPO245

Publications (Crossref)

Works10

Web history (Wayback)

Domainevogene.com

Wikidata

QIDQ6981538

Certificate / subdomain footprint

Subdomains38

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)512838723
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated1999-10-10
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityלא מוגבלת
In violation (unfiled)no
Last annual report2006
Active charges / liens0
Registry events0
Registered addressגד פינשטיין 13 רחובות